Neurofibromatosis type 1 (NF1) was first described in 1882 by the German pathologist Von Recklinghausen.

Neurofibromatosis type 2 (NF2) was first described in 1820 by the Scottish surgeon JH Wishart.

Von Recklinghausen

Clinical genetic testing can confirm the presence of a mutation in the neurofibromatosis type 1 (NF1) gene. Prenatal testing for NF1 mutations is also possible using amniocentesis or chorionic villus sampling procedures. Genetic testing for neurofibromatosis type 2 (NF2) mutations is sometimes available but is accurate only in about 65 percent of those individuals tested.

There are no available treatments for the disorders which underlie either type of neurofibromatosis. To some extent, the symptoms of NF-1 and NF-2 can be treated individually. Skin tumors can be surgically removed. Some brain tumors.

hereditary condition associated with an increased risk of bilateral acoustic neuromas, other nerve cell tumors and cataracts.